Nampt-IN-3
|
N647682-5mg
|
≥99% |
2121591-52-2 |
5mg
|
¥ 4500.9
|
期货,请咨询 |
阿拉丁 |
Nampt-IN-3
|
N647682-10mg
|
≥99% |
2121591-52-2 |
10mg
|
¥ 8000.9
|
期货,请咨询 |
阿拉丁 |
NF-κΒ activator 1
|
N647674-5mg
|
≥98% |
2387524-59-4 |
5mg
|
¥ 2210.9
|
期货,请咨询 |
阿拉丁 |
NF-κΒ activator 1
|
N647674-50mg
|
≥98% |
2387524-59-4 |
50mg
|
¥ 11390.9
|
期货,请咨询 |
阿拉丁 |
NF-κΒ activator 1
|
N647674-25mg
|
≥98% |
2387524-59-4 |
25mg
|
¥ 7140.9
|
期货,请咨询 |
阿拉丁 |
NF-κΒ activator 1
|
N647674-10mg
|
≥98% |
2387524-59-4 |
10mg
|
¥ 3570.9
|
期货,请咨询 |
阿拉丁 |
Niclosamide-13C6
|
N647673-5mg
|
≥99% |
1325808-64-7 |
5mg
|
¥ 4200.9
|
期货,请咨询 |
阿拉丁 |
Niclosamide-13C6
|
N647673-10mg
|
≥99% |
1325808-64-7 |
10mg
|
¥ 6800.9
|
期货,请咨询 |
阿拉丁 |
N-(3-Methoxybenzyl)Palmitamide
|
N647641-5mg
|
≥99% |
847361-96-0 |
5mg
|
¥ 2900.9
|
期货,请咨询 |
阿拉丁 |
N-(3-Methoxybenzyl)Palmitamide
|
N647641-10mg
|
≥99% |
847361-96-0 |
10mg
|
¥ 4400.9
|
期货,请咨询 |
阿拉丁 |
NHE3-IN-1
|
N647603-5mg
|
|
632355-68-1 |
5mg
|
¥ 500.9
|
期货,请咨询 |
阿拉丁 |
NHE3-IN-1
|
N647603-50mg
|
|
632355-68-1 |
50mg
|
¥ 2800.9
|
期货,请咨询 |
阿拉丁 |
NHE3-IN-1
|
N647603-25mg
|
|
632355-68-1 |
25mg
|
¥ 1750.9
|
期货,请咨询 |
阿拉丁 |
NHE3-IN-1
|
N647603-10mg
|
|
632355-68-1 |
10mg
|
¥ 830.9
|
期货,请咨询 |
阿拉丁 |
NHE3-IN-1
|
N647603-100mg
|
|
632355-68-1 |
100mg
|
¥ 4500.9
|
期货,请咨询 |
阿拉丁 |
Nav1.1 activator 1
|
N647552-5mg
|
≥99% |
2332897-85-3 |
5mg
|
¥ 3100.9
|
期货,请咨询 |
阿拉丁 |
Nav1.1 activator 1
|
N647552-50mg
|
≥99% |
2332897-85-3 |
50mg
|
¥ 15000.9
|
期货,请咨询 |
阿拉丁 |
Nav1.1 activator 1
|
N647552-10mg
|
≥99% |
2332897-85-3 |
10mg
|
¥ 4900.9
|
期货,请咨询 |
阿拉丁 |
ND-336
|
N647530-5mg
|
|
1807453-83-3 |
5mg
|
¥ 7000.9
|
期货,请咨询 |
阿拉丁 |
NRX-252262
|
N647521-5mg
|
≥99% |
2438637-61-5 |
5mg
|
¥ 3500.9
|
期货,请咨询 |
阿拉丁 |
NRX-252262
|
N647521-50mg
|
≥99% |
2438637-61-5 |
50mg
|
¥ 16500.9
|
期货,请咨询 |
阿拉丁 |
NRX-252262
|
N647521-25mg
|
≥99% |
2438637-61-5 |
25mg
|
¥ 9900.9
|
期货,请咨询 |
阿拉丁 |
NRX-252262
|
N647521-1mg
|
≥99% |
2438637-61-5 |
1mg
|
¥ 1800.9
|
期货,请咨询 |
阿拉丁 |
NRX-252262
|
N647521-10mg
|
≥99% |
2438637-61-5 |
10mg
|
¥ 5500.9
|
期货,请咨询 |
阿拉丁 |